ClC-3 is also overexpressed in hepatocellular carcinoma (HCC), CRC, and nasopharyngeal and breast cancers, where it facilitates tumour progression via Wnt/β-catenin and IGF/ERK signalling. The gene discussed is CLCN3; the disease is breast carcinoma.